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Purpose:  Controlled substance diversion does not discriminate and is detrimental to healthcare 
facilities and professionals alike. The problems identified in literature today are significant 
public health concerns being investigated at hospitals across the country to improve controlled 
substance surveillance and develop proactive diversion prevention programs.  Diversion is not a 
victimless crime.  The primary goal of investigating controlled substance diversion is improving 
public health, patient safety, and preventing substandard care.  Secondary goals are preventing 
and mitigating risks of the other components related to diversion such as the safety of health care 
worker, the environment, and the employer. 
Methods:  Current controlled substance practices will be investigated at a 631 bed tertiary care 
hospital and evaluated by direct observation, audits, and reporting.  Implementation of process 
and work flow enhancement will occur after initial investigation of the current situation.  A 
retrospective review of the controlled substance discrepancies will be audited for resolution.  A 
discrepancy is an event in which the physical count of controlled substances is more or less than 
expected.  The following data will be collected and assessed on a prospective basis for a 6 month 
period:  discrepancies not resolved within 24 hours by nursing unit, and total discrepancies by 
nursing unit.  All data will de-identified to maintain confidentiality.   
Results:  Following the initial intervention in April, the number of discrepancies not resolved 
within 24 hours fell from 144 to 66 (54.2% decrease) and total discrepancies from 242 to 172 
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(28.9% decrease).  The streamlined controlled substance discrepancy surveillance 
implementation will assist in detection and prevention of diversion. 
Conclusion:  It is anticipated that this project will demonstrate the need for an interdisciplinary 
approach to prevention of controlled substance diversion and medication safety at healthcare 
facilities.  The complexity and time intensive nature of controlled substance diversion 
identification, auditing, monitoring, education, and investigation will require a diverse team of 
healthcare professionals.  
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1.0  INTRODUCTION 
Approximately 110 individuals die every day from a drug overdose.1 The Centers for 
Disease Control and Prevention (CDC) state that prescription drug abuse and overdose are one of 
the top five health threats.2  Those effected by drug abuse and overdose extend beyond the 
individual addict.  Drug diversion is a dangerous method of obtaining drugs that leads to harm of 
all in contact with the addicted individual. 
Drug diversion is the act of illegally obtaining or using prescription medications not 
intended by the prescriber.  No one is immune to addiction or even the potential to divert 
prescription medications.  Healthcare professionals are not exempt from diversion to help 
maintain their dependence habits.  The scope of activities performed by individuals diverting 
medication may include personal use, sale, and illicit use.  When these actions are executed by 
healthcare professionals, the stakes are exceedingly high (Figure 1).  Figure 1 helps understand 
that healthcare professionals place unique threats to the health of themselves and others.  The 
victim of diversion is never solely one person.  Diversion is a multiple victim crime.  For 
healthcare professionals the potential victims are patients, co-workers, employer, and 
themselves.4  The scope of potential harm of diverting healthcare professionals include patients, 
co-workers, employers, and themselves.  Harm to patients may be substandard care from 
tampered medication, either complete absence or dilution of medication, experiencing pain and 
anxiety from inadequate treatment, infection spread, and general danger from intoxicated 
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healthcare professionals.  Harm to co-workers may include injury from uncapped needles and 
broken glass vials, infection of blood pathogens, liability of shared risk with patient care 
responsibilities, and disciplinary action from unwittingly aiding the addicted employee in 
violation of policies and procedures.  Harm to the employer may be through loss of revenue from 
medication, poor work quality, and absenteeism, liability of failure to prevent, recognize, or 
address signs of drug diversion, ethical obligation to past, present, and future patients, long term 
risk assessment management, mandatory reporting requirements of incidents becoming public 
knowledge and potentially highly publicized, and devastating effects on the institution from lack 
of patient trust, patients seeking care elsewhere, and damaging the ability to provide high quality 
patient centered care, which ultimately leads to decreased morale institution wide.  Harm to the 
addict includes overdose, death, infection, withdrawal symptoms, felony prosecution, civil 
malpractice actions, and actions against professional licenses.4   
The relation between workplace access to substances and prescription type dependence 
for healthcare professionals is limited.  An anonymous survey revealed 20% of nurses misused at 
least one prescription drug.5  This data indicated perceived availability, frequency of 
administration, and degree of workplace control over storage and dispensing are associated with 
an increased use of controlled substances by nurses.5  One out of fifteen pharmacists, one out of 
ten nurses, and one out of eight physicians are at risk of being dependent on controlled 
substances and/or alcohol.6  The Bureau of Labor Statistics from 2014 claims 297,100 
pharmacists, 2,751,000 registered nurses, and 708,300 physicians and surgeons currently exist in 
the United States.7  When combining these facts, the resulting numbers of possibly dependent 
pharmacist, nurses, and physicians are 44,565, 275,100, and 56,664 respectfully.  Consequences 
from healthcare professional’s diversion activities lead to widespread health issues.  Below is a 
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timeline of outbreaks associated with drug diversion by healthcare professionals (figure 1).  
Figure 1 outlines instances of known diversion that has led to adverse health outcomes.  Some 
healthcare professionals use dirty needles on themselves and patients, which increases the 
likelihood of disease spread.  Care for all victims of diversion is essential, especially through the 
assistance from federal, state, and healthcare facility regulations and policies.8,9 
Investigating discrepancies will identify targets for enhanced surveillance and develop a 
foundation for a proactive controlled substance diversion prevention program.  In order to 
achieve improved discrepancy surveillance a review of current controlled substance auditing and 
reporting practices for pharmacy and all nursing unit automated dispensing machines will be 
performed.  Educational materials will be created and distributed covering hospital policy, state 
regulations, and processes for how to resolve discrepancies successfully.  Monthly reports on 
discrepancies will be evaluated for pre and post educational implementation to identify areas in 
need of targeted surveillance and one-on-one education sessions.  Other reports will be identified 
to enhance surveillance techniques.  Pharmacy and nursing will reach out to administration, 
patient safety, quality, regulatory, and human resources with the results of the research to 
develop a proactive controlled substance diversion prevention plan. 
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Figure 1. United States Outbreaks Associated with Drug Diversion by Healthcare Providers, 1983-
20133 
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2.0  BACKGROUND 
2.1 POLICY ENVIRONMENT 
Expectations for the handling and management of controlled substances have existed for 
decades.  The basis for drug enforcement in the great majority of the states was established in 
1934 by the Uniform Narcotic Drug Act (UNDA).  The UNDA was replaced in 1970 by the 
Uniform Controlled Substance Act.  The classification of controlled substances has been defined 
since 1938 in Title 21 of Code of Federal Regulations.10  Federal legislation bestows major 
responsibility on individual states for enforcement of stricter regulations on controlled 
substances.  For example, the world of controlled substance discrepancies has become 
increasingly strained in Pennsylvania.  The Pennsylvania Department of Health has issued final 
guidance for acute healthcare facility determinations of reporting requirements under the 
Medical Care Availability and Reduction of Error (MCARE) Act on September 27, 2014 to be 
implemented on April 1, 2015.  The guidance is meant to enforce acute healthcare facilities to 
report all controlled substance discrepancies (resolved and unresolved).   Discrepancies are 
defined as the physical count of controlled substances being more or less than expected.  A 
discrepancy may include receiving orders from manufactures, removal, waste, or charting of 
controlled substances.  Discrepancies will occur for numerous reasons and require time for 
investigation and proper resolution if a true issue arises.  The most common forms of 
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discrepancies are human error of miscounting and operating system dysfunction, which are 
resolved in a timely manner. Discrepancies will stay in an unresolved state until proper 
resolution happens.  The nature of guidance published by the Department of Health was clear 
and consistent standards for the MCARE Act’s reporting requirements.  All hospitals within the 
state were expected to enhance reporting efforts equipped with these clarifications, especially 
controlled substance discrepancies.11  Controlled substance discrepancies are one method to 
report, investigate, and monitor for identification of diversion in healthcare facilities.  The 
methods of diversion detection are in a state of change across the country.  Diversion 
investigation is mainly reactive from anecdotal reports of behavior change or inconsistent 
practices.  This reactive method is no longer considered effective when utilized alone.  Proactive 
diversion detection and prevention methods are becoming the norm.  Two states, Minnesota and 
California, have formed coalitions to outline road maps to proactive diversion prevention 
programs.  These road maps are comprehensive in their approach to help find a solution to 
healthcare professional diversion.12,13 
2.2 STATE ENVIRONMENT 
Pennsylvania’s overdose death rate for 2010 is 15.3 per 100,000 population and above 
the national rate of 12.4 per 100,000 population.1  This crisis does not spare the western parts of 
Pennsylvania and creates devastation for families.  In 2014, approximately 2,489 Pennsylvanians 
died from a drug overdose.14 Reports on drug overdose deaths refer to all medications that are 
deemed the cause of death determined by toxicology results.14  Of the 2,489 overdose deaths, 
opioids, non-legal drugs, benzodiazepines, and antidepressants accounted for 25%, 24%, 18%, 
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and 17% of deaths, respectfully.14  The prescription opioid abuse cost insurers an estimated 
$72.5 billion in 2007.15   This financial toll reached into Medicaid programs, 65,000 Medicaid 
beneficiaries in five states incurred over $60 million in drug costs related to “doctor shopping” 
for opioid prescriptions.16   Fayette County has one of the highest death rates from drug 
overdoses in the country at 33.5 deaths per 100,000 residents.  Fayette County is followed by 
Greene County with 28.2, Beaver County with 24.2, Washington County with 21.2 deaths, 
Allegheny County with 20.5 deaths, Westmoreland County with 20.4 deaths, and Butler County 
with 17 deaths (all deaths per 100,000 residents).17  
 The rate of heroin related overdose deaths has increased from 2002 to 2013 by 286% in 
the United States.1 The majority of individuals who use heroin are also using at least one other 
drug and at risk to become addicted to heroin.  Individuals who use alcohol are two times for 
more likely, marijuana users are three times more likely, cocaine users are fifteen times more 
likely, and prescription opioid painkillers are forty times more likely to be addicted to heroin.18 
Heroin use has increased when examining rate amongst different demographic groups.1,18 
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Gender
Age
Race/
Ethnicity
Annual 
Household 
Income
Health 
Insurance 
Coverage
• 12-17yrs decreased by 11% (1.8 to 1.6)
• 18-25yrs increased by 109% (3.5 to 7.3)
• 26 or older increased by 58% (1.2 to 1.9)
• Non-Hispanic/White increased by 114% (1.4 to 3.0)
• Other decreased by 15% (2 to 1.7)
• Less than $20,000 increased by 62% (3.4 to 5.5)
• $20,000-$49,999 increased by 77% (1.3 to 2.3)
• $50,000 or more increased by 60% (1.0 to 1.6)
• None increased by 60% (4.2 to 6.7)
• Medicaid increased by 9% (4.3 to 4.7)
• Private or other increased by 63% (0.8 to 1.3)
• Male increased by 50% (2.4 to 3.6)
• Female increased by 100% (0.8 to 1.6)
 
Figure 2.  Comparing rates of heroin use in 2002-2004 and 2011-201315 
Opioid Epidemic in Pennsylvania 
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3.0  METHODS 
The initial process was to review the current controlled substance auditing and reporting 
practices at Allegheny General Hospital (AGH).    Allegheny General Hospital (AGH) is a 631 
licensed bed tertiary academic teaching hospital in Pittsburgh, Pennsylvania.  AGH is the largest 
of seven hospitals within the Allegheny Health Network.  A ‘Safe Infrastructure’ approach was 
utilized to assess proper controlled substance practices at AGH and guide implementation of the 
educational intervention.13  The word safe in ‘Safe Infrastructure’ is an acronym that stands for 
Safety teams/organizational structure, Access to information, Facility expectations, and Educate 
staff and patients.13  It was essential to have an understanding of the current state of controlled 
substance discrepancy reporting at AGH.  Best practices for controlled substances focus on many 
areas including procurement, storage and security, prescribing, preparation, dispensing, 
administration, handling waste, and follow-up if diversion is suspected.13  These categories are 
outlined in Appendix as they relate to AGH.  Controlled substance discrepancy reporting best 
practices include timely data collection to improve detection of questionable activity as outlined 
by Minnesota Department of Health and Minnesota Hospital Association.13  Timely data 
collection and discrepancy resolution is defined by institution.  AGH states no one is to leave the 
unit at change of shift until the count is accurate or staff are dismissed by the Charge Nurse or 
Manager of Hospital Operations (MHO).  An audit for all medications classified as controlled 
substances for all nursing units at AGH commenced.  The implementation plan for the audit 
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includes running reports monthly, starting January 2015 to July 2015, tabulating the total number 
of discrepancies including unresolved discrepancies and comparing them by nursing unit each 
month.  After the reports were analyzed and evaluated for three months the next step was to 
engage the nursing unit directors.  Without buy-in from the nursing unit directors a plan for 
intervention would not be possible.  The discrepancy findings from January 2015 to March 2015 
were sent to the nursing unit directors for input on process improvement.  
Education material was created to discuss proper discrepancy resolution methods, 
background information on discrepancies, and expectations moving forward.  Initial education 
was focused on key stakeholder groups of nursing and pharmacy.  The educational intervention 
was implemented on April 7, 2015 at the nursing managers meeting.  Another educational 
session was aimed at the nursing practice council on April 8, 2015.  The purpose of focused 
education for high level stakeholder groups was proper dissemination to front line employees.  
The educational content included review of AGH policy and procedures for controlled 
substances and discrepancy practice, description of MCARE Act reporting clarification, 
explanation of automated dispensing machine processes for creating, discovering, investigating 
and resolving discrepancies, demonstration of discrepancy practices through completed 
discrepancy examples, and contact information of key pharmacy employees to assist with 
investigation and reporting.  Timing of educational reinforcement of discrepancy policy and 
regulations was planned close to the MCARE Act reporting guidance clarification execution 
date.   
The targeted education phase of the discrepancy intervention happened one month later in 
May 2015.  Nursing units in the top 10% regarding unresolved discrepancies within twenty-four 
hours were educated at huddles.    Huddles or daily line ups are a component of the Ritz Carlton 
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leadership philosophy.  Daily huddles are performed at the beginning of every shift and normally 
last fifteen minutes.  These huddles serve as a method for team communication about strategy, 
roles of employees, and inspiration for winning attitudes.19  Brief education refreshers were 
covered at huddles for those targeted nursing units.  
The final intervention will be education at orientation for all new employees.  This will 
ensure dissemination to the entire nursing staff.  Continued evaluation of users consistently 
creating discrepancies will be analyzed.   
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4.0  RESULTS 
A streamlined controlled substance surveillance process and controlled substance task 
force team was developed in order to implement a proactive diversion prevention program.  The 
data collection ended early in May (figure 3) to focus on development of the controlled 
substance task force featured in table 1 and figure 4.  The number of discrepancies is not the 
amount of controlled substances, but the number of events.  The amounts of controlled 
substances vary for every discrepancy. 
During the interim data analysis a discussion with nursing leadership, pharmacy, and 
patient safety lead to an immediate action plan to form a committee.  The central tenants of the 
committee would be to establish a proactive diversion prevention program to address best 
practice development and implementation at AGH.  The states of Minnesota and California have 
developed and published roadmaps to proactive diversion prevention programs, which will serve 
as guidance for best practices.12,13  The beginning stages of AGH’s roadmap is outlined in 
Appendix.  The controlled substance prevention program champions are tasked to provide best 
practices and resources for AGH to prevent and increase awareness of controlled substance 
diversion, ensure all stakeholder groups work together toward common goals, create a better 
understanding of jurisdictional issues, and to meet state and federal reporting requirements of 
controlled substance diversion.13  The goals of the controlled substance program champions are 
based on the aforementioned published roadmaps.   
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Table 1.  Controlled Substance Prevention Program Champions at Allegheny General Hospital12,13 
 
Figure 3. 2015 Controlled Substance Discrepancies 
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Figure 4.  Main Components of The Controlled Substance Diversion Prevention Program12,13 
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5.0  DISCUSSION 
For the outlined research, several barriers existed.  First and foremost, controlled 
substance discrepancies are a limited source of diversion data.  Diversion is a complex process 
that will not be defined by any single act from an individual.  Healthcare facilities are at constant 
risk of diversion from employees.  The first basic steps are to comprehend regulations, policies, 
procedures, and the current status of diversion monitoring for any healthcare facility.  Different 
approaches should be applied when monitoring diversion.  Utilizing the same approach will 
teach diverters how to overcome monitoring tactics being used.  Leveraging software available 
or purchasing diversion prevention software is essential.  Most automated dispensing cabinet 
contracts include a software package such as CareFusion’s Knowledge Portal or Omnicell’s 
PandoraVIA or Medicast’s RxAuditor.  Without the software healthcare facilities are left to 
lengthy manual processes for monitoring controlled substance diversion.  Discrepancies are a 
key measure to audit, monitor, and report.  This enforces strict governance over controlled 
substances and denotes the severity when the counts do not match.  In order to move forward 
controlled substance discrepancies needed to be addressed by AGH.  Discrepancies were 
targeted and revealed the segments for further investigation, monitoring, and proactive 
prevention programming. 
Beyond the sheer magnitude of diversion, other limitations exist.  Nurses are under 
pressure when caring for high acuity patients, which places delays on resolving discrepancies 
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due to the busy workflow associated with this patient population.  Discrepancies may be resolved 
within the appropriate twenty four hour time frame, yet there is the possibility of inaccurate 
resolution.  Ensuring appropriate resolution of discrepancies involves time consuming 
investigation.  Each week greater than eight hours are spent taking a deeper dive into 
investigation of discrepancy reports.  Time is a major factor, which complicates the discrepancy 
resolution process.  The time a discrepancy is created could be on a Friday, yet the controlled 
substance is not used very often and no one accesses that controlled substance again until 
Tuesday and finds the discrepancy.  It has now been five days since the actual cause of the 
discrepancy, which makes resolution more difficult.   
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6.0  CONCLUSION 
The scope of this project exposed opportunities for improvement amongst all healthcare 
facilities.  Diversion prevention is not a simple cure.  Resources and toolkits for understanding 
this epidemic plaguing individuals and methods of eradication are being developed.  This 
research project has demonstrated a unique pharmacist-based role for prevention of controlled 
substance diversion and medication safety.  Pharmacy is taking the lead on the controlled 
substance task force and building a road map to proactive diversion prevention at Allegheny 
General Hospital.  Opportunities for process improvement are abundant after collecting and 
analyzing the discrepancy data.  The controlled substance task force is committed to the 
following future actions: 
• Annual controlled substance diversion competencies health system wide 
• Development of a process for timely accurate discrepancy resolution 
• Development of a proactive diversion program noted in the Appendix 
• Upgrade controlled substance diversion software and technology 
The importance of proactive diversion prevention is protection of the multiple victims being 
harmed by individuals afflicted with dependence from controlled substances and/or alcohol.  
This protection extends to the individual diverter themselves.  Healthcare professionals and 
facilities, allow this to be your call to action.  Care for yourself, your co-worker, your facility, 
and most importantly your patients. 
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APPENDIX: INITIAL ROAD MAP OUTLINE 
 
Road Map to Controlled Substance Diversion Prevention 
Component  Specific Action(s) Self-Assessment Checklist 
Safety Teams/ 
Organizational 
Structure 
1.  Organization 
defines Controlled 
Substance (CS) 
Diversion Prevention 
Program. 
1a. The organization has an interdisciplinary team involve 
in developing and overseeing the CS Diversion Prevention 
Program. 
 
1b. The CS Diversion Prevention Program includes 
prevention, detection and investigation. 
 
1c. The CS Diversion Prevention Program is reviewed by the 
team and updated at least annually. 
 
1d. CS Diversion Prevention Program champions have been 
identified and have designated clear roles with expectations 
from the following areas: 
 
• Medical Staff 
• Pharmacy 
• Nursing 
• Security 
• Human Resources 
• Patient Safety/Risk Management/Compliance 
• Administration 
•Legal (as necessary) 
• Communication (as necessary) 
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2. An organizational 
structure is in place 
that supports an 
effective CS Diversion 
Prevention Program. 
2a. The organization has a designated coordinator(s) for 
the CS Diversion Prevention Program. 
 
2b. The coordinator(s) has dedicated time to serve in this 
coordination function. 
 
2c. The organization has a team prepared to respond to 
suspected CS diversion situations. 
 
2d. The organization has and regularly reviews policies and 
procedures addressing all aspects of the CS use processes.  
 
2e. The organization regularly reviews policies and 
procedures to assure compliance with state and federal laws. 
3. Organization 
proactively 
collaborates with 
local law 
enforcement. 
3a. The organization (e.g. security) has engaged local law 
enforcement (e.g. county sheriff, chief of police) to discuss 
the CS Diversion Prevention Program and establish a 
communication strategy (including public) prior to CS 
diversion situations. 
4. Organization fulfills 
all reporting 
requirements for 
diversion or loss of 
CS. 
4a. ►The owner reports to the Pennsylvania Board of 
Pharmacy within thirty days of discovery of any CS losses, 
including their amounts and strengths.  
 
4b. ►The DEA registrant or their designee reports any CS 
theft or significant loss to the DEA within one business day of 
discovery.  
 
4c. ►The organization follows other applicable 
requirements.  For example, Medicare Conditions of 
Participation states: “Abuses and loss of controlled 
substances must be reported in accordance with applicable 
Federal and State laws, to the individual responsible for the 
pharmaceutical service, and to the chief executive officer, as 
appropriate.” 
Access to 
Information / 
Accurate 
Reporting / 
Monitoring / 
Surveillance / 
1. Organization 
reviews and audits 
relevant data that 
could indicate 
potential CS 
diversion. 
1a. ►The organization has a process to generate 
controlled substance data on a minimum monthly basis such 
as controlled substance surveillance reports, high user report, 
CS use through reports/log-sheets and CS “Disposition and 
Inventory” sheets. 
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Detection 
System 
2. Organization tracks 
and reviews 
measures 
recommended by 
Medication Safety 
Committee or other 
designated groups 
reporting directly to a 
Medical Staff 
Committee. 
2a. ►The organization has a process in place to review and 
analyze CS data on a regular basis.  
 
2b. ►The organization shares findings from the data analysis 
on a regular basis.  
 
2c. ►There is a process in place to activate a response team 
that includes a patient care manager, pharmacy Human 
Resources (HR) and security when diversion is suspected.  
 
2d. ►The organization has a process in place to contact law 
enforcement when diversion or theft is suspected. 
Facility 
Expectations 
1. Organization 
communicates the 
expectation that staff 
“speak up” when 
they become aware 
of an issue related to 
CS diversion. 
1a. ►Senior leadership has clearly communicated that all 
staff are to speak up and will be supported in speaking up 
when they become aware of possible diversion.  
 
1b. ►The hospital treats such information as confidential 
and takes all reasonable steps to protect the confidentiality 
of the information and the identity of the employee 
furnishing information.  
2. Organization 
establishes full 
disclosure policy. 
2a. ►The organization has a clearly define full disclosure 
policy and process to communicate to patients/families who 
are affected by CS diversion.  
3. The organization’s 
HR practices support 
an effective 
organization-wide CS 
Diversion Prevention 
Program. 
3a. The organization has established and communicate 
ways for staff to speak up anonymously (e.g. hot line, paper 
or electronic submission).  
 
3b. The organization has a process in place to remove an 
impaired caregiver from patient care  
 
3c. ►The organization conducts pre-employment 
background checks for Licensed Independent Practitioners 
(LIPs) and employees.  
 
3d. A log of staff photographs and signatures are maintained 
as appropriate.  
 
3e. The organization has a process to manage employee 
access to CS in a timely fashion when terminated or 
transferred.  
 
3f. The organization has developed a “for cause” policy for 
drug testing. 
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4. Organization does 
not allow sharing of 
pass codes. 
4a. ►The organization establishes and enforces a policy of 
not sharing pass codes such as electronic medical record 
(EMR), Automated Distribution Machine (ADM) and 
pharmacy door codes. 
Educate Staff 
(and Patients) 
1. Organization has in 
place an effective 
and comprehensive 
training and 
education program 
for all staff on CS 
diversion prevention. 
1a. The CS Diversion Prevention Program team has 
attended CS diversion prevention and statutory requirement 
training (e.g. National Association of Drug Diversion 
Investigators [NADDI], professional associations, licensing 
boards, state, local and federal law enforcement).  
 
1b. Expectations and supporting education have be 
incorporated into training for all new staff and LIPs.  
 
1c. Expectations and training include, at a minimum, 
providing awareness training to know the signs of diversion.  
 
1d. Resources are available to support employees and LIPs, 
e.g. Employee Assistance Program (EAP) and Health 
Professional Services Program(HPSP).  
 
1e. The facility requires training on CS policies and 
procedures prior to authorizing staff to have CS access. 
 
1f. The facility provides ongoing staff education at least 
annually to promote safe handling of CS and CS diversion 
awareness. 
 
1g. The organization provides patient education on safe 
medication handling, including potential for diversion. 
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Handling Waste 1. The organization’s 
“waste” handling 
practices maintain 
chain of custody to 
minimize the risk for 
CS diversion. 
Pharmacy:  
 
1a. CS waste from Compounded sterile Product (CSP) 
preparation in the Pharmacy is collected and randomly 
assayed. 
 
Areas outside Pharmacy:  
 
1b. ►Unusable product (UP) CS are to be immediately 
wasted and witnessed by health care professionals per 
specific hospital procedures.  
 
1c. All Potentially Reusable Product (PRP) drugs are returned 
to the pharmacy for evaluation of re-use/re-issue.  
 
1d. The organization has identified the high-risk areas (e.g. 
surgical, anesthesia, procedural) where CS diversion occurs.  
 
1e. The organization has identified specific high-risk CS 
medications (e.g., fentanyl) that are randomly assayed.  
 
1f. The organization has a process to randomly obtain and 
assay UP CS.  For random assays, the UP CS would not be 
subject to immediate witnessed waste. 
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2. The organization’s 
practices for handling 
unused CS, empty CS 
containers or CS 
returned to 
pharmacy minimize 
the risk of diversion. 
Wasting of UP CS: 
 
2a. ►Approved methods for wasting a CS are defined per 
federal, state and county laws and regulations  
 
2b. ►The wasting of all CS requires an independent license 
witness and must be documented in the ADM or via proof of 
use form, except when UP CS are returned to pharmacy for 
assay.  
 
2c. ►An individual witnessing CS wasting verifies the 
volume/amount being wasted matches the documentation 
and physically watches the medication being wasted per 
policy.  
 
2d. ►Empty containers of CS (e.g., vials) are discarded in 
limited access waste containers. 
 
2e. ►Waste containers with trace UP CS are secured to 
prevent tampering. 
 
2f. ►The pharmacy accounts for manufacturer overfill in 
injectable containers.  All overfill amounts are captured, 
verified, documented, and wasted accordingly. Controlled 
substance overfill should be considered unusable product 
(UP). 
 
PRP Returns: 
 
2g. PRP ADM managed CS are returned to a secure return 
bin/pocket and not to the original ADM pocket. 
 
2h. ►All PRP CS returns to pharmacy require chain of 
custody documentation in the patient care area and in 
pharmacy 
 
Waste or Reverse Distribution: 
 
2i. ►DEA registrant or their designee assists with all phases 
of transfer of CS to a reverse distributor and/or hazardous 
waste disposal company. 
 
2j. Expired CS that are quarantined for reverse distribution 
are properly accounted by way of a log or inventory list. The 
items sent back via reverse distribution could be reconciled 
with the reverse distribution log of CS.  
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Monitoring of 
CS and Process 
if Diversion is 
Suspected 
1. Organization 
removes access to CS 
if diversion is 
suspected. 
1a. ►All personnel actions (.g. suspension, terminations and 
resignations) are promptly communicated to pharmacy so 
access to CS can be removed.  
 
1b. ►If the hospital becomes aware of an arrest of an 
employee for illicit use of CS, the hospital immediately 
conducts its own investigation. The organization assesses 
whether to suspend, transfer, terminate or take other action 
(e.g., remove access to CS) against the employee. 
2. Organization 
regularly monitors CS 
through inventory, 
reports and audits. 
2a. CS purchase invoices are compared to CS orders and 
receipt into the pharmacy’s perpetual inventory. Any CS 
purchases outside of the pharmacy department are tracked. 
Since the invoice-receipt pair may both be removed with CS 
diversion, invoices also are reconciled to statements or 
wholesale purchase history reports to detect missing 
invoices.  
 
2b. Movement of CS throughout the hospital is tracked. For 
example, reports match narcotic vault transactions with 
receipt into ADM and/or paper inventory record with RN 
signature of receipt. 
 
2c. ►CS within an ADM or narcotic vault are inventoried at 
least monthly. 
 
2d.Non-automated CS storage areas are inventoried at each 
shift change. 
 
2e. ADM reports are reviewed at least monthly by pharmacy 
or patient care managers as define by the organization. 
Reports compare ADM activity with medication 
administration record. 
 
2f. ADM CS activity is compared to peers with similar staffing 
responsibilities and FTE appointments. 
 
2g. Transaction activity (e.g. inventory abnormalities removal 
of quantities greater than prescribed dose, cancellations, 
returns and waste) is compared to peers. 
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2h. Patient MAR: amount and quantity administered, is 
compared to what other caregivers administer on 
subsequent 
shifts (without patient change in condition). 
 
2i.Non-ADM CS storage area record of use is compared with 
MAR (e.g. anesthesia record, sedation record, eMAR) to 
assure 
appropriate documentation of waste. 
3. A process is in 
place to resolve CS 
discrepancies. 
3a. ►CS discrepancies are resolved upon discovery, no later 
than end of shift.  Discrepancies that cannot be resolved are 
jointly reviewed by pharmacy and patient care leadership 
with resolution within 24hours (e.g. metric: unresolved 
nursing unit CS discrepancies > 24 hours/total nursing unit CS 
discrepancies should be ≤8 percent).  
4. Organization 
creates standard 
process to investigate 
potential diversion 
cases. 
4a. ►There is a standard process in place to investigate 
potential diversion cases. 
  
► Indicated a legal or regulatory requirement.  
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